AstraZeneca’s Breztri Aerosphere Approved for COPD

The FDA has approved AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).

The approval was based on positive results from a phase 3 trial of the drug in patients with moderate to very severe COPD.

Breztri Aerosphere is under review in the EU for the treatment of COPD and is already approved in Japan and China.